191 related articles for article (PubMed ID: 37031211)
1. Conformational cycle of human polyamine transporter ATP13A2.
Mu J; Xue C; Fu L; Yu Z; Nie M; Wu M; Chen X; Liu K; Bu R; Huang Y; Yang B; Han J; Jiang Q; Chan KC; Zhou R; Li H; Huang A; Wang Y; Liu Z
Nat Commun; 2023 Apr; 14(1):1978. PubMed ID: 37031211
[TBL] [Abstract][Full Text] [Related]
2. Structural basis of polyamine transport by human ATP13A2 (PARK9).
Sim SI; von Bülow S; Hummer G; Park E
Mol Cell; 2021 Nov; 81(22):4635-4649.e8. PubMed ID: 34715013
[TBL] [Abstract][Full Text] [Related]
3. Cryo-EM reveals mechanistic insights into lipid-facilitated polyamine export by human ATP13A2.
Tomita A; Daiho T; Kusakizako T; Yamashita K; Ogasawara S; Murata T; Nishizawa T; Nureki O
Mol Cell; 2021 Dec; 81(23):4799-4809.e5. PubMed ID: 34798056
[TBL] [Abstract][Full Text] [Related]
4. Structural mechanisms for gating and ion selectivity of the human polyamine transporter ATP13A2.
Tillinghast J; Drury S; Bowser D; Benn A; Lee KPK
Mol Cell; 2021 Nov; 81(22):4650-4662.e4. PubMed ID: 34715014
[TBL] [Abstract][Full Text] [Related]
5. ATP13A2 deficiency disrupts lysosomal polyamine export.
van Veen S; Martin S; Van den Haute C; Benoy V; Lyons J; Vanhoutte R; Kahler JP; Decuypere JP; Gelders G; Lambie E; Zielich J; Swinnen JV; Annaert W; Agostinis P; Ghesquière B; Verhelst S; Baekelandt V; Eggermont J; Vangheluwe P
Nature; 2020 Feb; 578(7795):419-424. PubMed ID: 31996848
[TBL] [Abstract][Full Text] [Related]
6. Structure and transport mechanism of P5B-ATPases.
Li P; Wang K; Salustros N; Grønberg C; Gourdon P
Nat Commun; 2021 Jun; 12(1):3973. PubMed ID: 34172751
[TBL] [Abstract][Full Text] [Related]
7. ATP13A2-mediated endo-lysosomal polyamine export counters mitochondrial oxidative stress.
Vrijsen S; Besora-Casals L; van Veen S; Zielich J; Van den Haute C; Hamouda NN; Fischer C; Ghesquière B; Tournev I; Agostinis P; Baekelandt V; Eggermont J; Lambie E; Martin S; Vangheluwe P
Proc Natl Acad Sci U S A; 2020 Dec; 117(49):31198-31207. PubMed ID: 33229544
[TBL] [Abstract][Full Text] [Related]
8. α-Synuclein-induced dopaminergic neurodegeneration in a rat model of Parkinson's disease occurs independent of ATP13A2 (PARK9).
Daniel G; Musso A; Tsika E; Fiser A; Glauser L; Pletnikova O; Schneider BL; Moore DJ
Neurobiol Dis; 2015 Jan; 73():229-43. PubMed ID: 25461191
[TBL] [Abstract][Full Text] [Related]
9. Cryo-EM structures and transport mechanism of human P5B type ATPase ATP13A2.
Chen X; Zhou M; Zhang S; Yin J; Zhang P; Xuan X; Wang P; Liu Z; Zhou B; Yang M
Cell Discov; 2021 Nov; 7(1):106. PubMed ID: 34728622
[TBL] [Abstract][Full Text] [Related]
10. Hereditary Parkinsonism-Associated Genetic Variations in PARK9 Locus Lead to Functional Impairment of ATPase Type 13A2.
Park JS; Sue CM
Curr Protein Pept Sci; 2017; 18(7):725-732. PubMed ID: 26965689
[TBL] [Abstract][Full Text] [Related]
11. P5-ATPases: Structure, substrate specificities, and transport mechanisms.
Sim SI; Park E
Curr Opin Struct Biol; 2023 Apr; 79():102531. PubMed ID: 36724561
[TBL] [Abstract][Full Text] [Related]
12. Parkinson's disease-associated human P5B-ATPase ATP13A2 increases spermidine uptake.
De La Hera DP; Corradi GR; Adamo HP; De Tezanos Pinto F
Biochem J; 2013 Feb; 450(1):47-53. PubMed ID: 23205587
[TBL] [Abstract][Full Text] [Related]
13. The Parkinson-associated human P5B-ATPase ATP13A2 modifies lipid homeostasis.
Marcos AL; Corradi GR; Mazzitelli LR; Casali CI; Fernández Tome MDC; Adamo HP; de Tezanos Pinto F
Biochim Biophys Acta Biomembr; 2019 Oct; 1861(10):182993. PubMed ID: 31132336
[TBL] [Abstract][Full Text] [Related]
14. Novel Green Fluorescent Polyamines to Analyze ATP13A2 and ATP13A3 Activity in the Mammalian Polyamine Transport System.
Houdou M; Jacobs N; Coene J; Azfar M; Vanhoutte R; Van den Haute C; Eggermont J; Daniëls V; Verhelst SHL; Vangheluwe P
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830711
[TBL] [Abstract][Full Text] [Related]
15. Regulation of ATP13A2 via PHD2-HIF1α Signaling Is Critical for Cellular Iron Homeostasis: Implications for Parkinson's Disease.
Rajagopalan S; Rane A; Chinta SJ; Andersen JK
J Neurosci; 2016 Jan; 36(4):1086-95. PubMed ID: 26818499
[TBL] [Abstract][Full Text] [Related]
16. ATP13A2 Regulates Cellular α-Synuclein Multimerization, Membrane Association, and Externalization.
Si J; Van den Haute C; Lobbestael E; Martin S; van Veen S; Vangheluwe P; Baekelandt V
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33799982
[TBL] [Abstract][Full Text] [Related]
17. ATP13A2 modifies mitochondrial localization of overexpressed TOM20 to autolysosomal pathway.
Hatori Y; Kanda Y; Nonaka S; Nakanishi H; Kitazawa T
PLoS One; 2022; 17(11):e0276823. PubMed ID: 36445873
[TBL] [Abstract][Full Text] [Related]
18. Parkinson's disease-associated human ATP13A2 (PARK9) deficiency causes zinc dyshomeostasis and mitochondrial dysfunction.
Park JS; Koentjoro B; Veivers D; Mackay-Sim A; Sue CM
Hum Mol Genet; 2014 Jun; 23(11):2802-15. PubMed ID: 24399444
[TBL] [Abstract][Full Text] [Related]
19. Loss-of-function mutations in the ATP13A2/PARK9 gene cause complicated hereditary spastic paraplegia (SPG78).
Estrada-Cuzcano A; Martin S; Chamova T; Synofzik M; Timmann D; Holemans T; Andreeva A; Reichbauer J; De Rycke R; Chang DI; van Veen S; Samuel J; Schöls L; Pöppel T; Mollerup Sørensen D; Asselbergh B; Klein C; Zuchner S; Jordanova A; Vangheluwe P; Tournev I; Schüle R
Brain; 2017 Feb; 140(2):287-305. PubMed ID: 28137957
[TBL] [Abstract][Full Text] [Related]
20. Pathogenic effects of novel mutations in the P-type ATPase ATP13A2 (PARK9) causing Kufor-Rakeb syndrome, a form of early-onset parkinsonism.
Park JS; Mehta P; Cooper AA; Veivers D; Heimbach A; Stiller B; Kubisch C; Fung VS; Krainc D; Mackay-Sim A; Sue CM
Hum Mutat; 2011 Aug; 32(8):956-64. PubMed ID: 21542062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
